This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Obi Pharma Inc.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Innovations of Yin-Cheng Hsieh in Glycoprotein Engineering
Introduction
Yin-Cheng Hsieh is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of glycoprotein engineering, holding 2 patents that showcase his innovative approaches to synthesis and enzyme engineering.
Latest Patents
Hsieh's latest patents include methods for making high enantioselective secondary alcohols. This patent presents a new process for synthesizing compound OBI-3424 R-form and S-form products. The 'R-form' compound OBI-3423 was synthesized with an overall yield of 48% from compound OBI-3424-5 by installing the labile phosphate motif at a later stage. The stereochemistry is established through a five-step chemo-enzyme combination synthesis, achieving 99% optical purity. Subsequently, the 'S-form' compound OBI-3424 is prepared, improving the overall yield to 54% from compound OBI-3424-5, with excellent optical purity of 99% established through a four-step combination of chemo-enzyme synthesis.
Another significant patent involves glycosynthase variants for glycoprotein engineering and methods of use. This disclosure relates to novel glycosynthase enzymes designed for glycoprotein engineering and homogeneous antibody remodeling. The enzyme variants, EndoSd-D232M and EndoSz-D234M, exhibit glycan conjugation and modification activity at the conserved N297 glycosylation site of the Fc region of an exemplary antibody. These variants have demonstrated glycosynthase activities applicable to various monoclonal antibodies targeting different receptors, including Globo H, SSEA-4, SSEA-3 series of receptors, Herceptin, Perjeta, and Vectibix. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.
Career Highlights
Yin-Cheng Hsieh is currently associated with Obi Pharma Inc., where he continues to push the boundaries of innovation in his field. His work has garnered attention for its potential applications in therapeutic development and antibody engineering.
Collaborations
Hsieh collaborates
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile